Trial of Liposomal Bupivacaine for TKA

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

April 11, 2023

Study Completion Date

April 17, 2023

Conditions
Knee ReplacementTotal Knee ArthroplastyPost-Operative Pain
Interventions
DRUG

Liposomal bupivacaine

Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery

DRUG

Bupivacaine

Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery

Trial Locations (1)

04102

Northern Light Mercy Hospital, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

MaineHealth

OTHER

lead

Northern Light Mercy Hospital

OTHER

NCT05635916 - Trial of Liposomal Bupivacaine for TKA | Biotech Hunter | Biotech Hunter